UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 175

Sortiert nach

Inhibitors of HIV‑1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir

Journal of medicinal chemistry, 2018-01, Vol.61 (1), p.62-80

2018

Volltextzugriff (PDF)

Synthetic studies toward a simplified eleuthoside core

Medicinal chemistry research, 2023-07, Vol.32 (7), p.1376-1382

2023

Volltextzugriff (PDF)

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878

Antimicrobial agents and chemotherapy, 2023-05, Vol.67 (5), p.e0169422-e0169422

2023

Volltextzugriff (PDF)

In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

Antimicrobial Agents and Chemotherapy, 2012-07, Vol.56 (7), p.3498-3507

2012

Volltextzugriff (PDF)

Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action

Proteins, structure, function, and bioinformatics, 2015-02, Vol.83 (2), p.331-350

2015

Volltextzugriff (PDF)

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir

Medicinal chemistry research, 2021, Vol.30 (11), p.1955-1980

2021

Volltextzugriff (PDF)

Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties

European journal of medicinal chemistry, 2017-10, Vol.139, p.865-883

2017

Volltextzugriff (PDF)

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

Journal of medicinal chemistry, 2018-07, Vol.61 (14), p.6308-6327

2018

Volltextzugriff (PDF)

Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase

Journal of medicinal chemistry, 2014-03, Vol.57 (5), p.1855-1879

2014

Volltextzugriff (PDF)

Potent Long-Acting Inhibitors Targeting the HIV‑1 Capsid Based on a Versatile Quinazolin-4-one Scaffold

Journal of medicinal chemistry, 2023-02, Vol.66 (3), p.1941-1954

2023

Volltextzugriff (PDF)

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase

Antimicrobial agents and chemotherapy, 2014-06, Vol.58 (6), p.3485-3495

2014

Volltextzugriff (PDF)

Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV‑1 Protease Inhibitor Atazanavir

Journal of medicinal chemistry, 2019-04, Vol.62 (7), p.3553-3574

2019

Volltextzugriff (PDF)

Special issue of Medicinal Chemistry Research in honor of Dr. Nicholas A. Meanwell

Medicinal chemistry research, 2023-07, Vol.32 (7), p.1205-1207

2023

Volltextzugriff (PDF)

Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV‑1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs

Journal of medicinal chemistry, 2022-03, Vol.65 (6), p.4949-4971

2022

Volltextzugriff (PDF)

The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors

Advances in experimental medicine and biology, 2022, Vol.1366, p.45-64

2022

Volltextzugriff (PDF)

A survey of core replacements in indole-based HIV-1 attachment inhibitors

Bioorganic & medicinal chemistry letters, 2019-06, Vol.29 (11), p.1423-1429

2019

Volltextzugriff (PDF)

Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors

Bioorganic & medicinal chemistry, 2022-08, Vol.67, p.116833-116833, Article 116833

2022

Volltextzugriff (PDF)

(Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration

European journal of medicinal chemistry, 2020-12, Vol.207, p.112749, Article 112749

2020

Volltextzugriff (PDF)

AlMe3-Promoted Formation of Amides from Acids and Amines

Organic letters, 2012-01, Vol.14 (1), p.214-217

2012

Volltextzugriff (PDF)

Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV‑1 Protease Inhibitor Atazanavir

Journal of medicinal chemistry, 2018-05, Vol.61 (9), p.4176-4188

2018

Volltextzugriff (PDF)

Inhibitors of HIV-1 attachment. Part 7: Indole-7-carboxamides as potent and orally bioavailable antiviral agents

Bioorganic & medicinal chemistry letters, 2013-01, Vol.23 (1), p.198-202

2013

Volltextzugriff (PDF)

Discovery and Preclinical Profiling of GSK3839919, a Potent HIV‑1 Allosteric Integrase Inhibitor

ACS medicinal chemistry letters, 2022-06, Vol.13 (6), p.972-980

2022

Volltextzugriff (PDF)

Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery

Drug discovery today, 2014-09, Vol.19 (9), p.1288-1293

2014

Volltextzugriff (PDF)

Discovery and initial optimization of alkoxyanthranilic acid derivatives as inhibitors of HCV NS5B polymerase

Bioorganic & medicinal chemistry letters, 2017-01, Vol.27 (2), p.295-298

2017

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(161)

Publikationsform

Sprache

Englisch
(175)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inhibitors of HIV‑1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir

Synthetic studies toward a simplified eleuthoside core

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878

In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir

Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase

Potent Long-Acting Inhibitors Targeting the HIV‑1 Capsid Based on a Versatile Quinazolin-4-one Scaffold

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase

Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV‑1 Protease Inhibitor Atazanavir

Special issue of Medicinal Chemistry Research in honor of Dr. Nicholas A. Meanwell

Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV‑1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs

The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors

A survey of core replacements in indole-based HIV-1 attachment inhibitors

Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors

(Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration

AlMe3-Promoted Formation of Amides from Acids and Amines

Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV‑1 Protease Inhibitor Atazanavir

Inhibitors of HIV-1 attachment. Part 7: Indole-7-carboxamides as potent and orally bioavailable antiviral agents

Discovery and Preclinical Profiling of GSK3839919, a Potent HIV‑1 Allosteric Integrase Inhibitor

Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery

Discovery and initial optimization of alkoxyanthranilic acid derivatives as inhibitors of HCV NS5B polymerase

Suchergebnisse filtern